Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Expanded Access in Relapsed/Refractory Multiple Myeloma
NCT00179647Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Incidence of Adverse Events at 18.3 weeks and Overall Incidence of Adverse Events at 18.3 weeks. Started Sep 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00179647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179647.